Siegfried, a leading global CDMO, has officially inaugurated a new large-scale active pharmaceutical ingredient (API) production facility in Minden, Germany.

 

The expansion adds 100 m³ of reactor capacity, significantly strengthening Siegfried’s position among the world’s leading CDMOs for small-molecule drug substances. 

 

The company says the site will enhance its ability to deliver complex, high-quality, and scalable API manufacturing solutions to pharmaceutical partners worldwide.

 

CEO Marcel Imwinkelried described the opening as a key milestone in the company’s global growth strategy.

 

"The inauguration of our new Minden facility is an important milestone in the continued expansion of our global manufacturing network. It strengthens our ability to support customers with complex API manufacturing at commercial scale and underlines our commitment to reliable, flexible and high-quality supply."

 

The Minden plant integrates advanced process technology, high levels of automation, and enhanced containment systems. Features including gravity-flow processing, RFID-enabled recipe management, and optimized solvent handling are designed to improve both efficiency and production safety.

 

With the new facility now operational, Siegfried is further expanding its large-scale drug substance capabilities and reinforcing its focus on network resilience, operational excellence, and long-term partnerships with pharmaceutical customers.